EBS Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 32.52% compared to Emergent BioSolutions's net margin of 50.24%. Emergent BioSolutions's return on equity of -25.37% beat Johnson & Johnson's return on equity of 30.18%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 89.87%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 8.76%. Given that Emergent BioSolutions has higher upside potential than Johnson & Johnson, analysts believe Emergent BioSolutions is more attractive than Johnson & Johnson.

Emergent BioSolutions has a beta of 2.087, which suggesting that the stock is 108.653% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.23% to investors and pays a quarterly dividend of $1.30 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Emergent BioSolutions quarterly revenues are $209.1M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Emergent BioSolutions's net income of $68M is lower than Johnson & Johnson's net income of $11B. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 17.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.42x versus 4.22x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 32.52% compared to Emergent BioSolutions's net margin of -907.48%. Emergent BioSolutions's return on equity of -25.37% beat Moderna's return on equity of -29.23%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 89.87%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 57.17%. Given that Emergent BioSolutions has higher upside potential than Moderna, analysts believe Emergent BioSolutions is more attractive than Moderna.

Emergent BioSolutions has a beta of 2.087, which suggesting that the stock is 108.653% more volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $209.1M, which are larger than Moderna quarterly revenues of $107M. Emergent BioSolutions's net income of $68M is higher than Moderna's net income of -$971M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.42x versus 3.75x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of 32.52% compared to Emergent BioSolutions's net margin of -208.09%. Emergent BioSolutions's return on equity of -25.37% beat Nutriband's return on equity of -102.63%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 89.87%. On the other hand Nutriband has an analysts' consensus of $15.00 which suggests that it could grow by 39.93%. Given that Emergent BioSolutions has higher upside potential than Nutriband, analysts believe Emergent BioSolutions is more attractive than Nutriband.

Emergent BioSolutions has a beta of 2.087, which suggesting that the stock is 108.653% more volatile than S&P 500. In comparison Nutriband has a beta of 1.226, suggesting its more volatile than the S&P 500 by 22.565%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $209.1M, which are larger than Nutriband quarterly revenues of $667.4K. Emergent BioSolutions's net income of $68M is higher than Nutriband's net income of -$1.4M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.42x versus 49.61x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 32.52% compared to Emergent BioSolutions's net margin of 21.63%. Emergent BioSolutions's return on equity of -25.37% beat Pfizer's return on equity of 8.72%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 89.87%. On the other hand Pfizer has an analysts' consensus of $29.06 which suggests that it could grow by 14.79%. Given that Emergent BioSolutions has higher upside potential than Pfizer, analysts believe Emergent BioSolutions is more attractive than Pfizer.

Emergent BioSolutions has a beta of 2.087, which suggesting that the stock is 108.653% more volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.71% to investors and pays a quarterly dividend of $0.43 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $209.1M, which are smaller than Pfizer quarterly revenues of $13.7B. Emergent BioSolutions's net income of $68M is lower than Pfizer's net income of $3B. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.42x versus 2.31x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.